axelvento
7 months ago
With a float of 26 million shares and a market cap of $23 million, TRACON operates within the realm of oncology research and development. Envafolimab, one of TRACON’s key assets, has garnered both Fast Track Designation and Orphan Drug Designation. Envafolimab, a novel PD-L1 antibody, is administered via subcutaneous injection, offering a convenient treatment approach.
The pivotal Phase 3 trial for Envafolimab, known as ENVASARC, is anticipated to provide updated safety and efficacy data by the end of the first quarter of 2024, with final data expected in the second half of the same year. The study design, presented at the American Society of Clinical Oncology (ASCO) in the previous year, outlines primary endpoints focused on objective response rate (ORR) confirmed by independent central review. The trial aims to assess Envafolimab’s efficacy, particularly in refractory undifferentiated pleomorphic sarcoma (UPS) or myxofibrosarcoma (MFS) patients, with an ORR confirmed by BICR with 9/80 objective responses needed to exclude the known < 5% ORR of pazopanib, the only agent approved for patients with refractory UPS or MFS.
oldstocks
9 months ago
TCON needs to be over $1.124 by March 7th
To do that there has to be some good exciting news releases from now and then. The news would have to be so good that shorts would all want to cover.
The higher the stock runs the better chance it stays on NASDAQ
A reverse split is not going to get it there because there would be too few of outstanding shares.
As previously reported, on June 8, 2023, TRACON Pharmaceuticals, Inc. (the “Company”) received notices (the “Notices”) from Listing Qualifications staff of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that (i) for 30 consecutive business days preceding the date of the Notices, the market value of the Company’s common stock was less than $35.0 million, which does not meet the requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “Market Value Rule”) and the Company did not meet any of the alternative continued listing requirements set forth in Nasdaq Listing Rule 5550(b) (the “Financial and Liquidity Standards”), and (ii) for 30 consecutive business days preceding the date of the Notices, the closing bid price of the Company’s common stock was below $1.00 per share, which is the minimum required closing bid price for continued listing on the Nasdaq Capital Market pursuant to Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Company was provided 180 calendar days, or until December 5, 2023, to regain compliance with one of the Financial and Liquidity Standards and the Minimum Bid Price Requirement.
On December 12, 2023, the Company submitted a request for an oral appeal hearing before a Hearings Panel (the “Panel”). The hearing is scheduled to occur on March 7, 2024. Accordingly, the delisting and suspension of trading of the Company’s common stock described in the December 6 Notice will be stayed pending the issuance of the Panel’s final written decision. There can be no assurance that a favorable decision will be obtained from the Panel or that the Company will be successful in maintaining the listing of its common stock on the Nasdaq Capital Market.
oldstocks
11 months ago
TJ.. i posted this yesterday on another board
We bought TCON in hopes to make a profit.
I bought as high as .3089 and as low as .1862
I am not worried i am just waiting for the fluctuations. TCON is now heavily shorted.
They will have to buy back shares.
Tracon the company said it has licensed its proprietary PDP of CRO-independent clinical research to a clinical-stage biotech firm for a $3M upfront payment.
Latest news with Inhibrix is a big deal.
Under the deal, TRACON granted a non-exclusive and non-transferable license of its PDP to the clinical-stage biotech company for the design, conduct, and administration of clinical trials and related research and development activities, among others.
“We are now in a position to widely license our PDP to allow clinical-stage biotechnology and pharmaceutical companies to transform their clinical operations with the expectation of potentially dramatic cost reductions and shorter clinical trial timelines,” said CEO Charles Theuer.
About Inhibrix
Ticker INBX $20.54
$337 million in cash, so they have the money for the $3 Million deal.
https://inhibrx.com/wp-content/uploads/2023/11/Inhibrx-Presentation-Nov-2023.pdf
On November 17, 2023 (the “Effective Date”), Tracon Pharmaceuticals, Inc. (the “Company”) entered into a License Agreement (the “Agreement”) with Inhibrx, Inc. (“Inhibrx”). Under the terms of the Agreement, the Company granted a non-exclusive and non-transferable license of its product development platform to Inhibrx for the design, conduct and administration of clinical trials and related research and development activities, including activities relating to regulatory filings, submissions and approvals (the “Tracon PDP License”). The Tracon PDP License will allow Inhibrx to use the Company’s configuration documentation with a widely used software package in addition to use of the Company’s validation and qualification of the software package, and the Company’s standard operation procedure documents, policies, work instructions, and clinical operation templates (the “Licensed Technology”). Upon Inhibrx’s request during the first six months after the Effective Date, the Company is obligated to provide up to 500 hours of training (“Technical Support”) to Inhibrx. Pursuant to the Agreement, Inhibrx will make an upfront payment of $3.0 million to the Company, plus a potential $0.2 million (i) upon the completion of the Technical Support by the Company, or (ii) six months following the Company’s delivery of the Licensed Technology, whichever is earlier.
rayank
11 months ago
A lot in the pipeline: "TRACON Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted therapeutics for cancer. The Company’s lead product candidate, envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma. The Company’s other product candidates are YH001, a CTLA-4 antibody that is in Phase I/II development for the treatment of sarcoma; TRC102, a small molecule that is in Phase II clinical development for the treatment of mesothelioma; TJ004309, a CD73 antibody that is in Phase I testing, that is being developed through a collaboration with I-Mab Biopharma, and multiple bispecific antibody programs in preclinical development that are being developed through a collaboration with I-Mab Biopharma. The Company offers partners a solution for the clinical development and commercialization of their products in the United States."
smile